Next Article in Journal
Pericytes of Stria Vascularis Are Targets of Cisplatin-Induced Ototoxicity: New Insights into the Molecular Mechanisms Involved in Blood-Labyrinth Barrier Breakdown
Next Article in Special Issue
How Do Plants Cope with DNA Damage? A Concise Review on the DDR Pathway in Plants
Previous Article in Journal
Microporous Biocarbons Derived from Inonotus obliquus Mushroom and Their Application in the Removal of Liquid and Gaseous Impurities
Previous Article in Special Issue
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 24
10.3390/ijms232415789
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients

by
Giorgia Gurioli
1,
Gianluca Tedaldi
1,*,
Alberto Farolfi
2,
Elisabetta Petracci
3,
Claudia Casanova
4,
Giuseppe Comerci
5,
Rita Danesi
6,
Valentina Arcangeli
6,
Mila Ravegnani
6,
Daniele Calistri
1,
Valentina Zampiga
1,
Ilaria Cangini
1,
Eugenio Fonzi
3,
Alessandra Virga
1,
Davide Tassinari
7,
Marta Rosati
7,
Paola Ulivi
1,† and
Ugo De Giorgi
2,†
1
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
2
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
3
Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
4
Oncology Department, Santa Maria Delle Croci Hospital, 48121 Ravenna, Italy
5
Department of Obstetrics and Gynaecology, AUSL Romagna, Santa Maria Delle Croci Hospital, 48121 Ravenna, Italy
6
Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
7
Department of Oncology, Ospedale Infermi, 47923 Rimini, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2022, 23(24), 15789; https://doi.org/10.3390/ijms232415789
Submission received: 18 October 2022 / Revised: 1 December 2022 / Accepted: 8 December 2022 / Published: 13 December 2022
(This article belongs to the Special Issue DNA Damage Repair in Cancer: Genetics, Molecular Mechanisms, Diagnostic and Therapeutic Perspectives)
Versions Notes

Abstract

BRCA1 and BRCA2 are the most frequently mutated genes in ovarian cancer (OC) crucial both for the identification of cancer predisposition and therapeutic choices. However, germline variants in other genes could be involved in OC susceptibility. We characterized OC patients to detect mutations in genes other than BRCA1/2 that could be associated with a high risk of developing OC and permit patients to enter the most appropriate treatment and surveillance program. Next-generation sequencing analysis with a 94-gene panel was performed on germline DNA of 219 OC patients. We identified 34 pathogenic/likely pathogenic variants in BRCA1/2 and 38 in other 21 genes. The patients with pathogenic/likely pathogenic variants in the non-BRCA1/2 genes mainly developed OC alone compared to the other groups that also developed breast cancer or other tumors (p = 0.001). Clinical correlation analysis showed that the low-risk patients were significantly associated with platinum sensitivity (p < 0.001). Regarding PARP inhibitors (PARPi) response, the patients with pathogenic mutations in the non-BRCA1/2 genes had worse PFS and OS. Moreover, a statistically significantly worse PFS was found for every increase of one thousand platelets before PARPi treatment. To conclude, knowledge about molecular alterations in genes beyond BRCA1/2 in OC could allow for more personalized diagnostic, predictive, prognostic, and therapeutic strategies for OC patients.
Keywords: ovarian cancer; BRCA1/2; cancer predisposition; platinum sensitivity; PARP inhibitors; platelets ovarian cancer; BRCA1/2; cancer predisposition; platinum sensitivity; PARP inhibitors; platelets

Share and Cite

MDPI and ACS Style

Gurioli, G.; Tedaldi, G.; Farolfi, A.; Petracci, E.; Casanova, C.; Comerci, G.; Danesi, R.; Arcangeli, V.; Ravegnani, M.; Calistri, D.; et al. Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. Int. J. Mol. Sci. 2022, 23, 15789. https://doi.org/10.3390/ijms232415789

AMA Style

Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, et al. Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. International Journal of Molecular Sciences. 2022; 23(24):15789. https://doi.org/10.3390/ijms232415789

Chicago/Turabian Style

Gurioli, Giorgia, Gianluca Tedaldi, Alberto Farolfi, Elisabetta Petracci, Claudia Casanova, Giuseppe Comerci, Rita Danesi, Valentina Arcangeli, Mila Ravegnani, Daniele Calistri, and et al. 2022. "Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients" International Journal of Molecular Sciences 23, no. 24: 15789. https://doi.org/10.3390/ijms232415789

APA Style

Gurioli, G., Tedaldi, G., Farolfi, A., Petracci, E., Casanova, C., Comerci, G., Danesi, R., Arcangeli, V., Ravegnani, M., Calistri, D., Zampiga, V., Cangini, I., Fonzi, E., Virga, A., Tassinari, D., Rosati, M., Ulivi, P., & De Giorgi, U. (2022). Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. International Journal of Molecular Sciences, 23(24), 15789. https://doi.org/10.3390/ijms232415789

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop